Category Archives: Myocardial Infarction

David Stone Reoperations for bleeding are cut in half among patients who receive protamine during carotid endarterectomy, a new study has found. That was the main finding revealed by David Stone (Dartmouth-Hitchcock Medical Center, Lebanon, USA) at the 33rd Annual Meeting of the European Society for Vascular Surgery (ESVS 2019; 2427 September, Hamburg, Germany). Continue reading →

This transcript has been edited for clarity. Continue reading →

Intravenous tissue-type plasminogen activator (IV-rtPA) for acute ischemic stroke may be given to patients with recent or concurrent myocardial infarction (MI), but consideration should be given to the type of MI and time elapsed between the events, according to study results published in Stroke. While previously the American Heart Association/American Stroke Association guidelines considered MI within the preceding 3 months an absolute contraindication to IV-rtPA use, more recent guidelines consider this option reasonable. Continue reading →

Short-term geomagnetic disturbances driven by solar activity have been linked to a broad range of adverse health effects. In this blog,author Carolina Leticia Zilli Vieira discusses her recent article, published in Environmental Health, which looks at the effects of GMD on cardiovascular diseases, myocardial infarction, and stroke in 263 U.S. Cities Continue reading →

Cardiorenal disease is commonly the first cardiovascular disease (CVD) manifestation in patients with type 2 diabetes (T2D) without a history of CVD disease, significantly increasing risk for all-cause mortality in this patient population, according to study results presented at the 55th Annual Meeting of the European Association for the Study of Diabetes, held September 16 to 20, 2019, in Barcelona, Spain. Using healthcare insurance claims registries in Germany and Japan and full population registries from Norway and Sweden, researchers collected data from patients with T2D without a history of CVD or chronic kidney disease (CKD; n=687,732) Continue reading →

BARCELONA Results of the landmark DAPA-HF trialshowing that the glucose-lowering drug dapagliflozin (Farxiga, AstraZeneca) provides "quite stunning, pretty consistent benefit" in patients with heart failure, both with and without type 2 diabetes, were published online September 19 in the New England Journal of Medicine. Continue reading →

In patients with transient ST-segment elevation myocardial infarction (STEMI), both delayed invasive treatment and immediate invasive treatment result in similar good clinical outcomes 1 year later, according to study results published in JACC Cardiovascular Interventions. The study included a total of 142 patients age > 18 (mean age, 61.711.3) years, who presented with an acute STEMI with complaints of any duration and ST-segment elevations 2 mm in 2 standard limb leads or 2 contiguous chest leads during a prehospital electrocardiogram. The patients also had to exhibit spontaneous, complete resolution of ST-segment elevation and complete relief of symptoms with or without treatment Continue reading →

In the United States, proton pump inhibitors (PPIs) are one of the most widely used classes of drugs and are the most effective drugs for treating Gastroesophageal reflux disease (GERD). Continue reading →

Ryan M. Ridenour CHICAGO Preoperative opioid exposure was linked with significant perioperative consequences and postoperative complications in patients who underwent foot and ankle surgery, according to a presenter at the American Orthopaedic Foot & Ankle Society Annual Meeting Continue reading →

PARIS Dual therapy with the novel oral anticoagulant (NOAC) edoxaban (Savaysa, Daiichi Sankyo) and a P2Y12 inhibitor was noninferior to triple therapy with a vitaminK antagonist, a P2Y12 inhibitor, and aspirin to prevent major bleeding after successful stenting in patients with atrial fibrillation (AF). The P2Y12 inhibitor was clopidogrel (Plavix, Sanofi) in 93% of the patients, and rarely ticagrelor (Brilinta/Brilique, AstraZeneca) or prasugrel (Effient, Lilly/Daiichi Sankyo). Andreas Goette Andreas Goette, MD, professor and head, Department of Cardiology and Intensive Care Medicine, St.Vincenz Hospital, Paderborn, Germany, presented results from the Edoxaban Treatment Versus VitaminK Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI) trial during a press briefing and a hotline session here at the European Society of Cardiology Congress 2019 Continue reading →